- Home
- HNRG vs ATXS Comparison
HNRG vs ATXS Comparison
Compare HNRG & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNRG
- ATXS
- Stock Information
- Founded
- HNRG 1949
- ATXS 2008
- Country
- HNRG United States
- ATXS United States
- Employees
- HNRG N/A
- ATXS N/A
- Industry
- HNRG Coal Mining
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- HNRG Energy
- ATXS Health Care
- Exchange
- HNRG Nasdaq
- ATXS Nasdaq
- Market Cap
- HNRG 823.6M
- ATXS 676.1M
- IPO Year
- HNRG N/A
- ATXS 2015
- Fundamental
- Price
- HNRG $20.77
- ATXS $12.66
- Analyst Decision
- HNRG Strong Buy
- ATXS Buy
- Analyst Count
- HNRG 4
- ATXS 7
- Target Price
- HNRG $20.00
- ATXS $30.00
- AVG Volume (30 Days)
- HNRG 473.7K
- ATXS 4.2M
- Earning Date
- HNRG 11-10-2025
- ATXS 11-12-2025
- Dividend Yield
- HNRG N/A
- ATXS N/A
- EPS Growth
- HNRG N/A
- ATXS N/A
- EPS
- HNRG N/A
- ATXS N/A
- Revenue
- HNRG $419,451,000.00
- ATXS N/A
- Revenue This Year
- HNRG $11.19
- ATXS N/A
- Revenue Next Year
- HNRG $4.79
- ATXS N/A
- P/E Ratio
- HNRG N/A
- ATXS N/A
- Revenue Growth
- HNRG N/A
- ATXS N/A
- 52 Week Low
- HNRG $8.13
- ATXS $3.56
- 52 Week High
- HNRG $22.44
- ATXS $12.72
- Technical
- Relative Strength Index (RSI)
- HNRG 54.84
- ATXS 82.13
- Support Level
- HNRG $19.92
- ATXS $12.40
- Resistance Level
- HNRG $21.24
- ATXS $12.72
- Average True Range (ATR)
- HNRG 1.00
- ATXS 0.23
- MACD
- HNRG -0.07
- ATXS 0.01
- Stochastic Oscillator
- HNRG 45.74
- ATXS 86.92
About HNRG Hallador Energy Company
Hallador Energy Co is a coal mining company with operations in Indiana, USA, and it is part of the electric power generation industry. The operations of the company are divided into two primary reportable segments, the Coal Operations and Electric Operations segments. The majority of revenue is earned from the Coal Operations segment.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.